Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OCSAW by emailGet an email when OCSAW reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OCSAW, unsubscribe in one click. Privacy
📣 What OCSAW Says Is Next
this year · “This transaction comes at an opportune time, as Privosegtor is advancing rapidly through key regulatory milestones, including the ongoing PIONEER-1 registrational trial for optic neuritis and an expected IND submission for acute MS relapse later this year.”
Company press release, Aug 10, 2026 · SEC filing
late 2026 · “In 2025, following a successful FDA alignment meeting, we initiated the registrational PREDICT-1 trial in DED, with topline results anticipated around late 2026.”
Company press release, Apr 21, 2026 · SEC filing
Q4 2026 · “Topline results from PREDICT-1 are expected in Q4 2026.”
Company press release, Mar 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Sep 30, 2026 ·
Leadership Lionel Carnot resigned from the Board of Directors of Oculis Holding AG, effective September 30, 2026, after nearly a decade of service since 2017. The company says the departure is a personal decision, not a disagreement, and the board will have eight members. Form 6-K · SEC filing · Press release
Aug 10, 2026 ·
Deal Oculis agreed to acquire Accure Therapeutics' rights to Privosegtor (ACT-01) and preclinical ACT-02 for a $3.8 million cash upfront payment plus up to 2,050,000 ordinary shares. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Get the full OCSAW picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCSAW and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.